Science and Technology Department of the City of Shanghai recently announced the list of the 4th batch of National Science and Technology-based Small and Medium-sized Enterprises in 2022 in which NK CellTech, as an invisible unicorn company in the field of tumor immunotherapy, was listed in the database.

Science and technology-based SMEs refer to the middle and small-sized enterprises who achieve sustainable development by transforming their own intellectual properties achieved through scientific and technological research and developments made by a certain number of scientific and technological personnel into high-tech products or services. The database listing evaluation is a comprehensive evaluation made in accordance with the requirements of “Evaluation Methods for Science and Technology-based SMEs” jointly issued by the Ministry of Science and Technology, the Ministry of Finance and the State Taxation Administration and other requirement regard to scientific and technological personnel, R&D investment, scientific and technological achievements as well as proportion of R&D expenses of the company and other metrics.

As an important source of scientific and technological innovations, such SMEs play a vital role in strengthening the dominant role of enterprise innovation. The listing of NK CellTech in the database of Science and Technology SMEs marks a solid step towards a technology innovative enterprise. The company will leverage this recognition as an opportunity to accelerate its independent innovation, continue to increase R&D investment, cultivate a team of hi-tech personnel and build a more complete technological innovation system to promote the development and transformation of cell therapies continuously.

NK CellTech is a biotech company focusing on the discovery and development of innovative technology of NK cell therapy. The R&D team has over 30 years of experiences in the research and clinical practice of NK cells, which dedicates NK CellTech to become an international leading company in cellular immunotherapy. With our ABCDE-NK® platform (Allogeneic, Blood-derived, Cryopreserved Off-The-Shelf, Designed Genetically On Demand, Expanded to Clinical Scale) and SynNK™ platform (genetic logic gate technology of synthetic immunology), NK CellTech will deliver the innovative cellular drugs to precisely target broaden spectrum of tumors and harness the adaptivity to tumor immune microenvironment (TIME), leading to the consistent development of “intelligent” NK cell products to fulfil the unmet clinical needs of cancer patients.